AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36902217
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Trial: 36902861
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for displaced DRFs
Trial: 36902861
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for minimally or non-displaced DRFs
Trial: 36902861
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for both groups
Trial: 36904251
Drug: Walnut supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut supplementation (15% of daily energy)
Trial: 36905161
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (E-Stim) on both gastrocnemius muscles for 1 hour daily for 4 weeks
Trial: 36905498
Drug: TV-46000 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV-46000 (subcutaneous LAI antipsychotic agent)
Trial: 36905771
Drug: Fulvestrant (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (500 mg on days 0, 14 and 28, then every 28 ± 3 days, n = 77)
Trial: 36905771
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg/day, n = 67)
Trial: 36905980
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + ECIG retraining
Trial: 36905980
Drug: CC only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC only retraining
Trial: 36906081
Drug: Polysaccharide hemostatic
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide hemostatic powder (PHP) with diluted epinephrine injection and powder application as spray
Trial: 36906081
Drug: Conventional endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional endoscopic treatment (electrical coagulation or hemoclipping after diluted epinephrine injection)
Trial: 36906664
Drug: CD46-targeted alpha
RxNorm normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD46-targeted alpha therapy based on YS5
Trial: 36906664
Drug: Microtubule inhibitor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtubule inhibitor-based antibody drug conjugate
Trial: 36906875
Drug: Intravenous CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CYT107 (10 µg/kg)
Trial: 36906875
Drug: Intravenous CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CYT107
Trial: 36906875
Drug: Intramuscular CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular CYT107 (previous study)
Trial: 36907945
Drug: M-DEPTH depression
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-DEPTH depression care model (including antidepressants and individual Problem Solving Therapy)
Trial: 36907947
Drug: Alofanib (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alofanib (350 mg/m2, administered daily intravenously 5 days on, 2 days off)
Trial: 36907997
Drug: Antenatal azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antenatal azithromycin (500 mg oral tablets)
Trial: 36908150
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg pitavastatin
Trial: 36908150
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg pitavastatin/10 mg ezetimibe (K-924 LD)
Trial: 36908150
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg pitavastatin/10 mg ezetimibe (K-924 HD)
Trial: 36908150
Drug: Pitavastatin/ezetimibe fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin/ezetimibe fixed-dose combination
Trial: 36908150
Drug: Pitavastatin/ezetimibe fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin/ezetimibe fixed-dose combination and pitavastatin monotherapy
Trial: 36908314
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg per day
Trial: 36908609
Drug: High-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroids treatment
Trial: 36908619
Drug: ApTOLL (Toll-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL (Toll-like receptor 4 antagonist) administered together with endovascular treatment (EVT)
Trial: 36908619
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered together with endovascular treatment (EVT)
Trial: 36908766
Drug: Pain, depression,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain, depression, and anxiety medications
Trial: 36910457
Drug: Urinary L-type
RxNorm normalized name: hydroxypropyl cellulose (type L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary L-type fatty acid-binding protein (L-FABP) measured within 48 hours of admission
Trial: 36910457
Drug: L-FABP point
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-FABP point of care (POC) test
Trial: 36910501
Drug: Active acupuncture
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Trial: 36910501
Drug: Non-penetrating sham
RxNorm normalized name: Clearskin Pore Penetrating Black Mineral Mask
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-penetrating sham acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Trial: 36910537
Drug: Cardiac shock-wave
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac shock-wave therapy (CSWT)
Trial: 36910668
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy based on molecular profiles
Trial: 36910693
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
RxNorm normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) once daily for 48 weeks
Trial: 36911033
Drug: Early spontaneous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early spontaneous leg movements measured monthly from 1 to 4 months of age using inertial sensors
Trial: 36911944
Drug: Intrathecal onasemnogene
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal onasemnogene abeparvovec (medium dose)
Trial: 36912144
Drug: tDCS (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS (1 mA for 20 minutes) plus fifteen 45-minute sessions of naming treatment
Trial: 36912144
Drug: Sham-tDCS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-tDCS plus fifteen 45-minute sessions of naming treatment
Trial: 36912809
Drug: Immunotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy or chemo-immunotherapy
Trial: 36913518
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication intake
Trial: 36913694
Drug: Concurrent pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent pembrolizumab with AVD (doxorubicin, vinblastine, and dacarbazine)
Trial: 36913959
Drug: Monthly IPTp
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly IPTp with sulfadoxine-pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day)
Trial: 36913959
Drug: Monthly IPTp
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly IPTp with dihydroartemisinin-piperaquine (dosed by weight; three to five tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine once daily for 3 consecutive days)
Trial: 36913959
Drug: Monthly IPTp
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly IPTp with dihydroartemisinin-piperaquine plus azithromycin (two tablets containing 500 mg once daily for 2 consecutive days)
Trial: 36914185
Drug: COPDPredict with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPDPredict with rescue medication (RM)
Trial: 36914185
Drug: Standard self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard self-management plans with rescue medication (RM)
Trial: 36914193
Drug: Neoadjuvant arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant arterial embolisation chemotherapy (NAEC) with oxaliplatin 85 mg/m²
Trial: 36914591
Drug: Dexfadrostat phosphate
RxNorm normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfadrostat phosphate (DP13) 4 mg once daily for 8 days
Trial: 36914591
Drug: Dexfadrostat phosphate
RxNorm normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfadrostat phosphate (DP13) 8 mg once daily for 8 days
Trial: 36914591
Drug: Dexfadrostat phosphate
RxNorm normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfadrostat phosphate (DP13) 16 mg once daily for 8 days
Trial: 36914652
Drug: Trotabresib (RP2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trotabresib (RP2D of 45 mg/day 4 days on/24 days off or 30 mg/day 3 days on/11 days off)
Trial: 36914828
Drug: GB1211 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB1211 5, 20, 50, 100, 200, or 400 mg (single ascending-dose)
Trial: 36914828
Drug: GB1211 50
RxNorm normalized name: GB1211
DrugBank: GB1211 (DB17499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB1211 50 or 100 mg (multiple ascending-dose, twice daily for 10 days)
Trial: 36914946
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin in addition to standard treatment
Trial: 36914957
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation
Trial: 36915009
Drug: Cytokine profiles
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine profiles including IL-6, IL-10, IL-15, MDC, GRO, sCD40 L, G-CSF, and FGF-2.
Trial: 36915182
Drug: Epinephrine administration
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine administration during CPR
Trial: 36915199
Drug: Intranasal niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal niclosamide
Trial: 36915199
Drug: Nasal and
RxNorm normalized name: Nasal and Sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal and inhaled ciclesonide
Trial: 36915199
Drug: Intravenous sotrovimab
RxNorm normalized name: sotrovimab
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intravenous sotrovimab
Trial: 36915287
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (increasing RUTF amount with increasing weight)
Trial: 36915287
Drug: OptiMA strategy
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiMA strategy (decreasing RUTF dose with increasing weight and MUAC)
Trial: 36915288
Drug: hsTnT level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsTnT level >14 pg/mL
Trial: 36915288
Drug: hsTnT level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsTnT level ≤14 pg/mL
Trial: 36915613
Drug: Molecular-instructed therapy
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular-instructed therapy recommendations
Trial: 36915613
Drug: Initiated therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiated therapies based on MTB recommendations
Trial: 36916707
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human acyl ghrelin (0.1 µg/kg/min)
Trial: 36916707
Drug: Acyl ghrelin
RxNorm normalized name: gellan gum (low acyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyl ghrelin antagonist D-Lys 3
Trial: 36917037
Drug: Herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal drug combination identified by knowledge graph
Trial: 36917127
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) with care bundle including antibiotic prophylaxis, oral antibiotic prophylaxis (OAP), mechanical bowel preparation, laparoscopy, normothermia, and a wound retractor.
Trial: 36917429
Drug: Risankizumab (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (180 mg or 360 mg) delivered subcutaneously via on-body injector (OBI)
Trial: 36917758
Drug: Low-dose tamoxifen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tamoxifen 5 mg once daily for 3 years
Trial: 36918228
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for FM
Trial: 36918236
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose, 1000 mg
Trial: 36918236
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate (FS), ca. 200 mg every day
Trial: 36918234
Drug: Ileocolonic-delivered oral
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileocolonic-delivered oral vitamin B
Trial: 36918388
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects on GFR slope
Trial: 36918388
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects on UACR change
Trial: 36918388
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment effects on UACR change and GFR slope
Trial: 36918550
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg QD on Day 1-5
Trial: 36918550
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg QD with dorzagliatin 75 mg BID on Day 6-10
Trial: 36918550
Drug: Dorzagliatin 75
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 75 mg BID alone on Day 11-15
Trial: 36918896
Drug: GFC-NHS-POx patch
RxNorm normalized name: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFC-NHS-POx patch
Trial: 36918896
Drug: ORC-PLGA-NHS-POx: NU-POx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORC-PLGA-NHS-POx: NU-POx patch
Trial: 36919514
Drug: Haloperidol (HAL;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (HAL; 3-mg) or fluphenazine (FLU; 3-mg)
Trial: 36920397
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 mg oral twice daily)
Trial: 36920460
Drug: 5-month nonlinear
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-month nonlinear aerobic exercise program with 3 weekly sessions
Trial: 36920652
Drug: RRx-001 combined
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 combined with reintroduced chemotherapy (carboplatin/cisplatin and etoposide)
Trial: 36920745
Drug: Remimazolam tosylate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosylate (high dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Trial: 36920745
Drug: Remimazolam tosylate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosylate (low dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Trial: 36920756
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (insulin pump or multiple daily injections plus continuous glucose monitor)
Trial: 36921766
Drug: Sequential fractions
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential fractions (50 Gy/4f) to the lung
Trial: 36921902
Drug: Lactation cookies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactation cookies (LCs) with galactagogues (56.5 g daily for 1 month)
Trial: 36921902
Drug: Conventional cookies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional cookies (56.5 g daily for 1 month)
Trial: 36922497
Drug: Niraparib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib monotherapy (C1)
Trial: 36922593
Drug: Menin inhibitor
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menin inhibitor revumenib
Trial: 36922769
Drug: Adherence-enhancing interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence-enhancing interventions performed monthly for 3 consecutive months for adolescents with VL1 > 1000 copies/ml
Trial: 36922777
Drug: 90 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 µg of vitamin D supplementation
Trial: 36922777
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg of vitamin D supplementation
Trial: 36922785
Drug: Cilofexor 100
RxNorm normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor 100 mg once daily for up to 96 weeks
Trial: 36922785
Drug: Cilofexor 100
RxNorm normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor 100 mg daily (open-label) after the blinded phase
Trial: 36922805
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (41.4 Gy with 23 fractions) with concurrent chemotherapy (albumin-bound paclitaxel, 100 mg/m2) followed by tislelizumab.
Trial: 36922871
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both interventions (online risk-reduction intervention and HCV-RNA self-sampling)
Trial: 36922936
Drug: ZL-1211 (anti-CLDN18.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZL-1211 (anti-CLDN18.2 therapeutic antibody)
Trial: 36922962
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based intervention for procrastination; details on dosage and duration not available.
Trial: 36923108
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart one to three times daily
Trial: 36923108
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart three times daily with insulin detemir once daily
Trial: 36923108
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir once daily
Trial: 36923305
Drug: Mavorixafor monotherapy
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor monotherapy
Trial: 36923305
Drug: Mavorixafor in
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor in combination with pembrolizumab
Trial: 36923307
Drug: Pelabresib (CPI-0610)
RxNorm normalized name: pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelabresib (CPI-0610) 225 mg tablet daily
Trial: 36923454
Drug: Zilucoplan (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan (0.3 mg/kg daily subcutaneous)
Trial: 36923571
Drug: AV-101 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (1 mg, 3 mg, 10 mg, 30 mg, 90 mg)
Trial: 36923571
Drug: AV-101 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (10 mg, 30 mg, 90 mg)
Trial: 36923571
Drug: Oral imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral imatinib (400 mg)